EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
This article was originally published in The Pink Sheet Daily
Executive Summary
Remission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.